Large-Scale Production of Lentiviral Vectors: Current Perspectives and Challenges
Lentiviral vectors (LVs) have gained value over recent years as gene carriers in gene therapy. These viral vectors are safer than what was previously being used for gene transfer and are capable of infecting both dividing and nondividing cells with a long-term expression. This characteristic makes L...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-11-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/12/11/1051 |
| _version_ | 1797548862906302464 |
|---|---|
| author | Eduardo Martínez-Molina Carlos Chocarro-Wrona Daniel Martínez-Moreno Juan A. Marchal Houria Boulaiz |
| author_facet | Eduardo Martínez-Molina Carlos Chocarro-Wrona Daniel Martínez-Moreno Juan A. Marchal Houria Boulaiz |
| author_sort | Eduardo Martínez-Molina |
| collection | DOAJ |
| description | Lentiviral vectors (LVs) have gained value over recent years as gene carriers in gene therapy. These viral vectors are safer than what was previously being used for gene transfer and are capable of infecting both dividing and nondividing cells with a long-term expression. This characteristic makes LVs ideal for clinical research, as has been demonstrated with the approval of lentivirus-based gene therapies from the Food and Drug Administration and the European Agency for Medicine. A large number of functional lentiviral particles are required for clinical trials, and large-scale production has been challenging. Therefore, efforts are focused on solving the drawbacks associated with the production and purification of LVsunder current good manufacturing practice. In recent years, we have witnessed the development and optimization of new protocols, packaging cell lines, and culture devices that are very close to reaching the target production level. Here, we review the most recent, efficient, and promising methods for the clinical-scale production ofLVs. |
| first_indexed | 2024-03-10T15:06:49Z |
| format | Article |
| id | doaj.art-2abaf46db2a149519e367b33edf2c3ce |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-10T15:06:49Z |
| publishDate | 2020-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-2abaf46db2a149519e367b33edf2c3ce2023-11-20T19:40:30ZengMDPI AGPharmaceutics1999-49232020-11-011211105110.3390/pharmaceutics12111051Large-Scale Production of Lentiviral Vectors: Current Perspectives and ChallengesEduardo Martínez-Molina0Carlos Chocarro-Wrona1Daniel Martínez-Moreno2Juan A. Marchal3Houria Boulaiz4Biopathology and Medicine Regenerative Institute (IBIMER), University of Granada, 18016 Granada, SpainBiopathology and Medicine Regenerative Institute (IBIMER), University of Granada, 18016 Granada, SpainBiopathology and Medicine Regenerative Institute (IBIMER), University of Granada, 18016 Granada, SpainBiopathology and Medicine Regenerative Institute (IBIMER), University of Granada, 18016 Granada, SpainBiopathology and Medicine Regenerative Institute (IBIMER), University of Granada, 18016 Granada, SpainLentiviral vectors (LVs) have gained value over recent years as gene carriers in gene therapy. These viral vectors are safer than what was previously being used for gene transfer and are capable of infecting both dividing and nondividing cells with a long-term expression. This characteristic makes LVs ideal for clinical research, as has been demonstrated with the approval of lentivirus-based gene therapies from the Food and Drug Administration and the European Agency for Medicine. A large number of functional lentiviral particles are required for clinical trials, and large-scale production has been challenging. Therefore, efforts are focused on solving the drawbacks associated with the production and purification of LVsunder current good manufacturing practice. In recent years, we have witnessed the development and optimization of new protocols, packaging cell lines, and culture devices that are very close to reaching the target production level. Here, we review the most recent, efficient, and promising methods for the clinical-scale production ofLVs.https://www.mdpi.com/1999-4923/12/11/1051lentiviral vectorgene therapylarge-scale productionbioreactor |
| spellingShingle | Eduardo Martínez-Molina Carlos Chocarro-Wrona Daniel Martínez-Moreno Juan A. Marchal Houria Boulaiz Large-Scale Production of Lentiviral Vectors: Current Perspectives and Challenges Pharmaceutics lentiviral vector gene therapy large-scale production bioreactor |
| title | Large-Scale Production of Lentiviral Vectors: Current Perspectives and Challenges |
| title_full | Large-Scale Production of Lentiviral Vectors: Current Perspectives and Challenges |
| title_fullStr | Large-Scale Production of Lentiviral Vectors: Current Perspectives and Challenges |
| title_full_unstemmed | Large-Scale Production of Lentiviral Vectors: Current Perspectives and Challenges |
| title_short | Large-Scale Production of Lentiviral Vectors: Current Perspectives and Challenges |
| title_sort | large scale production of lentiviral vectors current perspectives and challenges |
| topic | lentiviral vector gene therapy large-scale production bioreactor |
| url | https://www.mdpi.com/1999-4923/12/11/1051 |
| work_keys_str_mv | AT eduardomartinezmolina largescaleproductionoflentiviralvectorscurrentperspectivesandchallenges AT carloschocarrowrona largescaleproductionoflentiviralvectorscurrentperspectivesandchallenges AT danielmartinezmoreno largescaleproductionoflentiviralvectorscurrentperspectivesandchallenges AT juanamarchal largescaleproductionoflentiviralvectorscurrentperspectivesandchallenges AT houriaboulaiz largescaleproductionoflentiviralvectorscurrentperspectivesandchallenges |